Related references
Note: Only part of the references are listed.Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
Michael Roth et al.
PEDIATRIC BLOOD & CANCER (2016)
Prevalence of HPV After Introduction of the Vaccination Program in the United States
Lauri E. Markowitz et al.
PEDIATRICS (2016)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner
L. Fernandez et al.
CANCER LETTERS (2015)
Regulatory T cells in cancer; can they be controlled?
Dennis O. Adeegbe et al.
IMMUNOTHERAPY (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Danielle M. Lussier et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
Mahiuddin Ahmed et al.
ONCOIMMUNOLOGY (2015)
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
Danielle M. Lussier et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients
Pooja Hingorani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Bispecific T-cell engagers for cancer immunotherapy
Amelia M. Huehls et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
Going Back to Class I: MHC and Immunotherapies for Childhood Cancer
Kellie B. Haworth et al.
PEDIATRIC BLOOD & CANCER (2015)
IGF1R-and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Xin Huang et al.
PLOS ONE (2015)
Ganglioside GD2 as a Therapeutic Target for Antibody-Mediated Therapy in Patients With Osteosarcoma
Michael Roth et al.
CANCER (2014)
CAR T Cells for Solid Tumors Armed and Ready to Go?
Sunitha Kakarla et al.
CANCER JOURNAL (2014)
Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer
Falguni Parikh et al.
CANCER RESEARCH (2014)
Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Valeria Leuci et al.
CURRENT GENE THERAPY (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
Johanna Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
New viruses for cancer therapy: meeting clinical needs
Tanner S. Miest et al.
NATURE REVIEWS MICROBIOLOGY (2014)
Initial Testing (Stage 1) of Glembatumumab Vedotin (CDX-011) by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Xiang Chen et al.
CELL REPORTS (2014)
Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Jacson K. Shen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRI lo/neg cells): the gateway to improved responses
Rebecca R. Laborde et al.
FRONTIERS IN IMMUNOLOGY (2014)
Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment
Gregory L. Beatty et al.
ONCOIMMUNOLOGY (2014)
Exomics and immunogenics Bridging mutational load and immune checkpoints efficacy
Stephane Champiat et al.
ONCOIMMUNOLOGY (2014)
Translational biology of osteosarcoma
Maya Kansara et al.
NATURE REVIEWS CANCER (2014)
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Li Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma
Deepa Kolaseri Krishnadas et al.
PEDIATRICS (2013)
Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
Jung Ryul Kim et al.
PLOS ONE (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Genetically Modified T cells Targeting Interleukin-11 Receptor α-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases
Gangxiong Huang et al.
CANCER RESEARCH (2012)
Progress of oncolytic viruses in sarcomas
Christina K. Lettieri et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma
Christophe Paget et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Myeloid-derived suppressor cells - their role in haemato-oncological malignancies and other cancers and possible implications for therapy
Tamar Tadmor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Mifamurtide for the treatment of nonmetastatic osteosarcoma
Kosei Ando et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Cytotoxic T-Lymphocyte Antigen-4+49G/A Polymorphism Is Associated with Increased Risk of Osteosarcoma
Wen Wang et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Duck Cho et al.
CLINICAL CANCER RESEARCH (2010)
Functional Roles of Osteoactivin in Normal and Disease Processes
Maneet Singh et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2010)
Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation
Selim Kuci et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Review of mifamurtide in the treatment of patients with osteosarcoma
Leo Kager et al.
Therapeutics and Clinical Risk Management (2010)
International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons
Lisa Mirabello et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression
Nabil Ahmed et al.
MOLECULAR THERAPY (2009)
KIR-HLA Receptor-Ligand Mismatch Associated With a Graft-Versus-Tumor Effect in Haploidentical Stem Cell Transplantation for Pediatric Metastatic Solid Tumors
Antonio Perez-Martinez et al.
PEDIATRIC BLOOD & CANCER (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats
Camille Chauvin et al.
CANCER RESEARCH (2008)
Negative signaling by inhibitory receptors: the NK cell paradigm
Eric O. Long
IMMUNOLOGICAL REVIEWS (2008)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
Paul A. Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel et al.
NATURE (2007)
Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity
Zhe Yu et al.
CANCER INVESTIGATION (2007)
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup
Ian J. Lewis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors:: use as a possible therapeutic approach of osteosarcoma -: art. no. 123
S Théoleyre et al.
BMC CANCER (2005)
Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma
K Pritchard-Jones et al.
BRITISH JOURNAL OF CANCER (2005)
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma
M Wölfl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma
S Ferrari et al.
CANCER (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis
A Saudemont et al.
BLOOD (2004)
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
ME Dudley et al.
JOURNAL OF IMMUNOTHERAPY (2003)
MHC class I antigens, immune surveillance, and tumor immune escape
A Garcia-Lora et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2003)
Primary metastatic osteosarcoma:: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols
L Kager et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
SS Bielack et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
